Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 20, Pages -Publisher
MDPI
DOI: 10.3390/ijms21207604
Keywords
glioma; oncolytic virus; glioblastoma; virotherapy
Funding
- Fondo de Investigaciones Sanitarias (FIS) [PI17-01489]
- Miguel Servet Program del Instituto de Salud Carlos III [CP11/00147]
- Ministerio de Economia y Competitividad-FEDERER [RTC-2016-4990-1]
- Consejeria de Educacion e Investigacion de la Comunidad de Madrid [NIETO-CM B2017/BMD-3731]
Ask authors/readers for more resources
Glioma tumors are one of the most devastating cancer types. Glioblastoma is the most advanced stage with the worst prognosis. Current therapies are still unable to provide an effective cure. Recent advances in oncolytic immunotherapy have generated great expectations in the cancer therapy field. The use of oncolytic viruses (OVs) in cancer treatment is one such immune-related therapeutic alternative. OVs have a double oncolytic action by both directly destroying the cancer cells and stimulating a tumor specific immune response to return the ability of tumors to escape the control of the immune system. OVs are one promising alternative to conventional therapies in glioma tumor treatment. Several clinical trials have proven the feasibility of using some viruses to specifically infect tumors, eluding undesired toxic effects in the patient. Here, we revisited the literature to describe the main OVs proposed up to the present moment as therapeutic alternatives in order to destroy glioma cells in vitro and trigger tumor destruction in vivo. Oncolytic viruses were divided with respect to the genome in DNA and RNA viruses. Here, we highlight the results obtained in various clinical trials, which are exploring the use of these agents as an alternative where other approaches provide limited hope.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available